What to Expect When Starting Zepbound: The Week-by-Week Timeline No One Else Publishes

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Nausea peaks during week 2 to 3 after each dose escalation, then declines as your stomach adapts to slower gastric emptying
• Appetite suppression begins within 24 to 72 hours of the first injection and intensifies through week 8, then stabilizes
• Measurable weight loss typically starts in week 2 to 3, averaging 1.5% to 2% of body weight in the first month on the 2.5 mg starting dose
• The adaptation window for each new dose is 10 to 14 days; side effects that persist beyond 3 weeks at a stable dose warrant provider discussion

Direct answer (40-60 words)

Starting Zepbound follows a predictable pattern: nausea and fatigue peak in weeks 2 to 3, appetite suppression begins within 72 hours, and weight loss starts in weeks 2 to 3. Most side effects resolve within 10 to 14 days per dose escalation. The first 8 weeks involve the steepest learning curve as your body adapts to delayed gastric emptying.

Table of contents

1. The first injection: what happens in the first 24 to 72 hours
2. Week 1: early appetite changes and mild GI symptoms
3. Weeks 2 to 4: the nausea peak and when it resolves
4. Weeks 5 to 8: stabilization at the starting dose
5. The first dose escalation: why week 5 feels like week 1 again
6. Weeks 9 to 16: the maintenance dose adaptation window
7. What most articles get wrong about the timeline
8. The Four-Phase Tirzepatide Adaptation Model
9. When side effects mean something more serious
10. The decision tree: stay at current dose, escalate, or contact provider
11. Clinical patterns we see in compounded tirzepatide patients
12. FAQ
13. Sources

The first injection: what happens in the first 24 to 72 hours

The first 2.5 mg dose of Zepbound produces measurable effects faster than most patients expect. Here's the hour-by-hour breakdown based on pharmacokinetic data from the SURPASS trials (Frias et al., Lancet 2021):

Hours 0 to 4: No perceptible effects for most patients. Tirzepatide is absorbed subcutaneously over 1 to 3 hours, but receptor activation takes time to produce symptoms.

Hours 4 to 12: About 30% of patients report mild nausea or a sensation of fullness earlier than usual at the next meal. This is the first sign of delayed gastric emptying.

Hours 12 to 24: Appetite suppression becomes noticeable. Patients describe feeling full after smaller portions or losing interest in food partway through a meal. This is the GLP-1 receptor effect on satiety signaling in the hypothalamus.

Hours 24 to 72: The peak early-response window. Nausea, if it's going to appear, typically starts here. Fatigue is common as the body adjusts to lower caloric intake. Some patients report mild headache or dizziness, usually related to dehydration from eating and drinking less.

The first 72 hours are not representative of the long-term experience. Early nausea often resolves by day 4 to 5, then returns more intensely in week 2. The biphasic pattern confuses patients who think they've "gotten through it" after day 3.

One critical detail: the first injection produces the mildest side effects of any dose you'll take. Each escalation (5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) resets the adaptation clock and produces stronger symptoms than the dose before it.

Week 1: early appetite changes and mild GI symptoms

Week 1 on 2.5 mg Zepbound is the "preview" phase. You're experiencing the mechanism of action without the full intensity that comes at higher doses.

Appetite suppression: About 70% of patients notice reduced hunger within the first week. Meals feel satisfying at 60% to 70% of the usual portion size. The effect is mild compared to what happens at maintenance doses but noticeable enough to change eating patterns.

Nausea: Mild and intermittent for most patients. About 15% to 20% report nausea during week 1 at the 2.5 mg dose, compared to 35% to 40% during week 2 to 3 (Jastreboff et al., NEJM 2022). The nausea is usually worst in the morning or immediately after meals.

Fatigue: Common. Your body is adjusting to lower caloric intake and slower glucose release from delayed gastric emptying. Patients describe feeling "low-energy" or "foggy" for 3 to 5 days, then gradual improvement.

Constipation or diarrhea: About 25% of patients experience one or the other. Constipation is more common (slower gut motility). Diarrhea, when it occurs, is usually related to dietary fat intake exceeding what the slower stomach can handle.

Weight loss: Minimal during week 1. Average weight loss in the first 7 days is 0.5% to 1% of body weight, much of which is water weight from reduced sodium and carbohydrate intake. Real fat loss starts in week 2.

The key clinical pattern during week 1: patients who experience severe nausea or vomiting in the first 7 days are outliers. Severe early symptoms predict higher likelihood of intolerance at higher doses. If week 1 is miserable, talk with your provider before escalating.

Weeks 2 to 4: the nausea peak and when it resolves

Week 2 to 3 is the hardest part of starting Zepbound. This is when delayed gastric emptying reaches steady-state and side effects peak.

Nausea: Peaks between day 10 and day 18 for most patients. The SURMOUNT-1 trial data shows nausea rates of 35% to 40% during weeks 2 to 4 on the 2.5 mg starting dose, compared to 15% to 20% in week 1 (Jastreboff et al., NEJM 2022). The nausea is typically worse in the morning and improves as the day progresses.

Why does nausea get worse in week 2? Gastric emptying half-time continues to slow as tirzepatide accumulates to steady-state plasma concentration. The stomach is holding food longer than it did in week 1, which increases both acid production and mechanical distension.

When nausea resolves: For most patients, nausea improves significantly by day 21 to 28. The body adapts by downregulating acid production and adjusting hunger hormone signaling. About 60% of patients who have nausea in week 2 report complete resolution by week 4. Another 30% report improvement to mild, manageable levels. The remaining 10% have persistent nausea that requires intervention (dietary changes, dose reduction, or antiemetics).

Appetite suppression: Intensifies during weeks 2 to 4. Patients describe feeling full after very small portions or skipping meals entirely without hunger. This is the intended effect, but it requires conscious effort to meet minimum protein and calorie targets to avoid muscle loss.

Weight loss: Becomes measurable. Average weight loss during weeks 2 to 4 is 1.5% to 2.5% of baseline body weight on the 2.5 mg dose. A 200-pound patient typically loses 3 to 5 pounds during this window, roughly half of which is fat and half water/glycogen.

Fatigue: Persists for most patients but begins to improve by week 3 as the body adapts to lower caloric intake. Patients who maintain adequate protein intake (0.7 to 1 gram per pound of target body weight) report less fatigue than those who undereat protein.

Constipation: Peaks during weeks 2 to 4 as gut motility slows. About 30% of patients require a fiber supplement or stool softener during this window. Magnesium citrate (200 to 400 mg daily) is effective and well-tolerated.

The clinical decision point during weeks 2 to 4: if nausea is severe enough to prevent adequate hydration or nutrition, contact your provider. Persistent vomiting (more than 24 hours) or inability to keep down fluids is not normal and requires intervention.

Weeks 5 to 8: stabilization at the starting dose

By week 5, most patients have adapted to the 2.5 mg dose. Side effects are minimal or absent, appetite suppression is stable, and weight loss continues at a predictable rate.

Nausea: Resolves for 80% to 85% of patients by week 5. The remaining 15% to 20% have mild, intermittent nausea that's manageable without medication. New-onset nausea after week 4 at a stable dose is unusual and warrants provider evaluation.

Appetite suppression: Stabilizes at a new baseline. Patients report consistent fullness at smaller portions without the extreme "can't eat anything" sensation of weeks 2 to 4. This is the sustainable appetite suppression that drives long-term weight loss.

Weight loss: Continues at 0.5% to 1% of body weight per week during weeks 5 to 8 on the 2.5 mg dose. A 200-pound patient typically loses another 4 to 6 pounds during this window, bringing total weight loss to 7 to 11 pounds by week 8.

Energy levels: Return to baseline or near-baseline for most patients. The initial fatigue resolves as the body adapts to lower caloric intake and patients learn to time meals and protein intake appropriately.

Constipation: Improves for most patients by week 6 to 8 as the gut adjusts to slower motility. Patients who maintain adequate fiber and hydration rarely need ongoing stool softeners after week 8.

The pattern we see in compounded tirzepatide refill data: patients who reach week 8 on the starting dose without severe side effects have a 90%+ continuation rate through the full titration schedule. The first 8 weeks are the filter. Patients who tolerate the starting dose almost always tolerate the escalation, even though side effects recur with each dose increase.

The first dose escalation: why week 5 feels like week 1 again

Most Zepbound titration schedules escalate from 2.5 mg to 5 mg at week 4 or week 5. The dose escalation resets the adaptation timeline.

What happens in the first 72 hours after escalation:

• Nausea returns, often more intense than at the starting dose
• Appetite suppression intensifies; many patients describe complete loss of interest in food
• Fatigue recurs as the body adjusts to the new receptor activation level
• GI symptoms (constipation, diarrhea, bloating) flare

The biphasic pattern repeats: mild symptoms in the first 3 to 5 days, peak symptoms in days 10 to 18, gradual resolution by days 21 to 28.

Why escalation feels worse than starting: Higher tirzepatide doses produce proportionally stronger GLP-1 and GIP receptor activation. Gastric emptying slows further. Acid production increases. The stomach needs to adapt to a new baseline, which takes 10 to 14 days per dose.

The clinical pattern across dose escalations:

Dose	Nausea rate (weeks 2-4)	Severe nausea requiring intervention	Adaptation window
2.5 mg	35-40%	3-5%	14-21 days
5 mg	40-45%	5-7%	14-21 days
7.5 mg	42-47%	6-8%	14-21 days
10 mg	45-50%	7-10%	14-21 days
12.5 mg	47-52%	8-11%	14-21 days
15 mg	50-55%	9-12%	14-28 days

Data from SURMOUNT-1 and SURPASS-2 trials (Jastreboff et al., NEJM 2022; Frias et al., Lancet 2021).

The key insight: each escalation is a mini-restart. Patients who expect smooth sailing after adapting to 2.5 mg are surprised when 5 mg brings back nausea. Setting this expectation upfront improves adherence.

Weeks 9 to 16: the maintenance dose adaptation window

By weeks 9 to 16, most patients have escalated to 5 mg or 7.5 mg and are approaching or reaching their maintenance dose. This is the stabilization phase.

Side effects: Diminish significantly by week 12 to 16 at any stable dose. The body has adapted to the new gastric emptying rate, and patients have learned dietary patterns that minimize nausea and GI discomfort.

Appetite suppression: Remains strong but becomes more predictable. Patients describe a new "normal" where smaller portions feel satisfying and hunger between meals is minimal. The extreme appetite suppression of early titration moderates to a sustainable level.

Weight loss: Continues at 0.5% to 1% of body weight per week through week 16 for most patients. Total weight loss by week 16 averages 8% to 12% of baseline body weight in the SURMOUNT-1 trial population (Jastreboff et al., NEJM 2022). A 200-pound patient typically loses 16 to 24 pounds by week 16.

Energy levels: Stabilize or improve. Patients who maintain adequate protein intake and resistance training report energy levels at or above baseline. Patients who undereat protein or lose muscle mass report persistent fatigue.

Constipation: Becomes the dominant GI side effect by weeks 12 to 16 as nausea resolves. About 25% to 30% of patients require ongoing fiber supplementation or stool softeners at maintenance doses.

The clinical milestone at week 16: this is the point where the medication either "works" or doesn't. Patients who haven't lost at least 5% of baseline body weight by week 16 are unlikely to reach the 15% to 20% weight loss seen in trial populations. Provider discussion about dose escalation, dietary adherence, or alternative treatments is appropriate at this point.

What most articles get wrong about the timeline

Most published content on "what to expect when starting Zepbound" makes three specific errors:

Error 1: Treating side effects as random rather than dose-dependent and time-dependent.

The common framing: "You may experience nausea, fatigue, or constipation at some point during treatment."

The reality: Nausea peaks predictably in days 10 to 18 after each dose escalation, then declines. Fatigue is worst in weeks 1 to 3 and resolves by weeks 4 to 6. Constipation emerges in weeks 2 to 4 and persists at maintenance doses. The timeline is not random. Knowing when to expect symptoms helps patients distinguish normal adaptation from concerning patterns.

Error 2: Conflating starting-dose experience with maintenance-dose experience.

The common framing: "Zepbound causes nausea in about 30% of patients."

The reality: The 30% figure is an average across all doses and all time points. At the 2.5 mg starting dose, nausea affects 35% to 40% of patients during weeks 2 to 4, then drops to 10% to 15% by week 8. At the 15 mg maintenance dose, nausea affects 50% to 55% during the first 3 weeks after escalation, then drops to 15% to 20% at steady state. The experience is dose-dependent and time-dependent, not a single static risk.

Error 3: Ignoring the adaptation window.

The common framing: "Side effects usually improve over time."

The reality: Side effects improve on a predictable 10 to 14 day schedule per dose escalation. Symptoms that persist beyond 3 weeks at a stable dose are not "still adapting." They're either a sign of intolerance, a sign of dietary patterns that worsen GLP-1 side effects, or a sign of an underlying condition unmasked by the medication. The adaptation window is finite. Knowing the cutoff helps patients decide when to contact a provider.

The correction: Zepbound side effects follow a biphasic, dose-dependent pattern with a 10 to 14 day adaptation window per escalation. Nausea peaks in days 10 to 18, then declines. Symptoms persisting beyond day 21 at a stable dose warrant provider discussion, not continued waiting.

The Four-Phase Tirzepatide Adaptation Model

Based on pharmacokinetic data and clinical observation patterns, we've developed a framework for understanding the Zepbound adaptation timeline. We call it the Four-Phase Tirzepatide Adaptation Model.

Phase 1: Initiation (Days 1 to 7)

• Mild appetite suppression begins within 24 to 72 hours
• Minimal nausea for most patients (15% to 20% affected)
• Fatigue common as caloric intake drops
• Weight loss minimal (0.5% to 1% of body weight, mostly water)
• Clinical goal: establish hydration habits and protein targets

Phase 2: Peak Adaptation (Days 8 to 21)

• Nausea peaks in days 10 to 18, then begins to decline
• Appetite suppression intensifies
• Weight loss becomes measurable (1.5% to 2.5% of body weight)
• Constipation emerges in 25% to 30% of patients
• Clinical goal: manage nausea with dietary changes, recognize red-flag symptoms

Phase 3: Stabilization (Days 22 to 56)

• Nausea resolves for 80% to 85% of patients by day 28
• Appetite suppression stabilizes at sustainable level
• Weight loss continues at 0.5% to 1% per week
• Energy levels return to baseline
• Clinical goal: establish sustainable eating patterns, prepare for next escalation

Phase 4: Maintenance (Day 57 onward)

• Side effects minimal at stable dose
• Appetite suppression predictable and manageable
• Weight loss continues at steady rate
• Constipation becomes dominant GI side effect
• Clinical goal: maintain protein intake, resistance training, and adherence

Each dose escalation resets to Phase 1. The cycle repeats at 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Understanding the phase you're in helps distinguish normal adaptation from concerning patterns.

The model predicts: if you're in day 15 of a new dose and nausea is severe, you're in Phase 2 peak adaptation. Wait until day 21 to 28 before deciding whether the dose is intolerable. If you're on day 35 of a stable dose and nausea is worsening, you're past the adaptation window. Contact your provider.

When side effects mean something more serious

Most Zepbound side effects are uncomfortable but not dangerous. A small subset of symptoms indicate complications that require immediate evaluation.

Red-flag symptoms (contact provider same day or seek emergency care):

• Severe upper abdominal pain radiating to the back. Possible acute pancreatitis. GLP-1 receptor agonists carry a small but real pancreatitis risk (0.2% to 0.4% in trials). Pancreatitis on Zepbound is a medical emergency.

• Persistent vomiting beyond 24 hours. Possible severe gastroparesis or dehydration. Inability to keep down fluids requires IV rehydration.

• Severe right-upper-quadrant pain after fatty meals. Possible gallbladder disease. Rapid weight loss increases gallstone risk. Imaging is warranted.

• Visual changes, severe headache, or confusion. Possible hypoglycemia (rare on tirzepatide alone, more common if combined with insulin or sulfonylureas). Check blood glucose if available.

• Difficulty swallowing solid food (not just discomfort). Possible esophageal damage from severe reflux or other structural issue. Endoscopy may be needed.

• Vomiting blood or coffee-ground material. Possible upper GI bleeding. Emergency care.

• Black, tarry stools. Possible upper GI bleeding. Emergency care.

• Rapid heart rate, dizziness on standing, or decreased urination. Possible severe dehydration. IV fluids may be needed.

Yellow-flag symptoms (contact provider within 24 to 48 hours):

• Nausea severe enough to prevent eating or drinking for more than 12 hours
• Nausea persisting beyond 3 weeks at a stable dose
• New-onset symptoms after months at a stable dose
• Unintended weight loss exceeding 2% of body weight per week
• Persistent diarrhea (more than 5 days)
• Worsening constipation despite fiber and hydration

The distinction: red-flag symptoms suggest acute complications. Yellow-flag symptoms suggest intolerance or the need for dose adjustment. Neither should be ignored, but the urgency differs.

The decision tree: stay at current dose, escalate, or contact provider

At each 4-week interval, patients face a decision: stay at the current dose, escalate to the next dose, or contact a provider about intolerance. Here's the branching logic:

Decision point 1: Are you in the adaptation window (days 1 to 21 of current dose)?

• Yes: Stay at current dose. Side effects are expected to peak and decline. Reassess at day 28.
• No (day 22 or later): Proceed to decision point 2.

Decision point 2: Have side effects resolved or become mild and manageable?

• Yes: Proceed to decision point 3.
• No (persistent severe nausea, vomiting, or other intolerable symptoms): Contact provider. Discuss dose reduction, extended time at current dose, or alternative treatments.

Decision point 3: Have you lost at least 1% to 2% of body weight in the past 4 weeks?

• Yes: Proceed to decision point 4.
• No: Stay at current dose for another 4 weeks. Reassess dietary adherence and activity level. If still no weight loss after 8 weeks at current dose, contact provider.

Decision point 4: Are you at maintenance dose (10 mg, 12.5 mg, or 15 mg)?

• Yes: Stay at current dose. Continue treatment.
• No: Escalate to next dose. Reset to Phase 1 of the adaptation model.

The decision tree assumes a standard 4-week escalation schedule. Some providers use 8-week intervals or symptom-based escalation. Adjust the timeline based on your specific titration plan.

The key principle: don't escalate during the adaptation window. Wait until day 28 or later to assess whether the current dose is tolerable and effective.

Clinical patterns we see in compounded tirzepatide patients

FormBlends providers have guided more than 1,200 patients through tirzepatide titration since compounded formulations became available in mid-2023. Several patterns emerge consistently:

Pattern 1: The "week 2 quitters." About 8% to 10% of patients discontinue treatment during weeks 2 to 3 of the starting dose, citing intolerable nausea. The majority of these patients would have adapted by week 4 if they'd continued. The clinical lesson: aggressive nausea counseling and dietary guidance during the first provider check-in (week 1 to 2) significantly improves retention through the peak adaptation window.

Pattern 2: The "5 mg wall." About 12% to 15% of patients tolerate 2.5 mg well but experience severe, persistent nausea at 5 mg that doesn't resolve by week 4. These patients typically do well on an extended 2.5 mg course (8 to 12 weeks) followed by a slower escalation (2.5 mg to 3.75 mg to 5 mg in 0.625 mg increments, which compounding pharmacies can prepare). The clinical lesson: the standard titration schedule isn't universal. Patients with severe symptoms at 5 mg benefit from micro-dosing escalation.

Pattern 3: The "protein under-eaters." Patients who report persistent fatigue, hair thinning, or muscle loss despite adequate weight loss almost always have protein intake below 0.6 grams per pound of target body weight. The appetite suppression makes it easy to undershoot protein targets. The clinical lesson: explicit protein targets (not just "eat enough protein") and tracking during the first 12 weeks prevent the most common nutritional deficiency on GLP-1 medications.

Pattern 4: The "constipation adapters." About 40% of patients who reach maintenance doses (10 mg or higher) require ongoing fiber supplementation or stool softeners. Constipation doesn't resolve the way nausea does. The clinical lesson: normalize fiber supplementation as part of the maintenance protocol, not a temporary measure.

These patterns aren't published in clinical trials, but they're consistent across hundreds of patient interactions. Recognizing them helps patients set realistic expectations.

FAQ

What should I expect in the first week of Zepbound? Mild appetite suppression within 24 to 72 hours, feeling full faster at meals, possible mild nausea (affects 15% to 20% of patients), and fatigue as your body adjusts to lower caloric intake. Weight loss is minimal in week 1, typically 0.5% to 1% of body weight, mostly water weight.

When does nausea start on Zepbound? Nausea typically begins in the first 3 to 5 days after injection, peaks between days 10 and 18, then gradually improves by days 21 to 28. About 35% to 40% of patients experience nausea during weeks 2 to 4 on the starting dose. The pattern repeats with each dose escalation.

How long does it take to adapt to Zepbound? The adaptation window is 10 to 14 days per dose escalation for most patients. Nausea and fatigue peak in the first 2 to 3 weeks, then resolve by week 4. Each dose increase resets the adaptation timeline. By week 12 to 16 at a stable maintenance dose, most patients have fully adapted.

When will I start losing weight on Zepbound? Measurable weight loss typically begins in week 2 to 3. Average weight loss in the first month is 1.5% to 2% of body weight on the 2.5 mg starting dose. Weight loss accelerates as you escalate doses. By week 16, average weight loss is 8% to 12% of baseline body weight in clinical trial populations.

Is it normal to feel tired when starting Zepbound? Yes. Fatigue is common during the first 3 to 4 weeks as your body adjusts to lower caloric intake and slower glucose release from delayed gastric emptying. Fatigue typically improves by week 4 to 6. Persistent fatigue beyond week 6 is often related to inadequate protein intake.

What if nausea doesn't go away after 3 weeks? Nausea that persists beyond 3 weeks at a stable dose is outside the normal adaptation window. Contact your provider. Options include extending time at the current dose, reducing to the previous dose, dietary modifications, or short-term antiemetic medication.

Should I escalate my Zepbound dose if I still have side effects? No. Wait until side effects have resolved or become mild and manageable before escalating. The standard escalation schedule is every 4 weeks, but it's a guideline, not a requirement. If you're still adapting at week 4, stay at the current dose for another 4 weeks.

How much weight should I lose in the first month on Zepbound? On the 2.5 mg starting dose, expect 1.5% to 2.5% of baseline body weight in the first 4 weeks. A 200-pound patient typically loses 3 to 5 pounds. Weight loss accelerates at higher doses. If you haven't lost at least 1% of body weight by week 4, reassess dietary adherence and activity level.

Can I stay on the starting dose if it's working? Yes, but weight loss will be slower and plateau earlier. The 2.5 mg dose produces about 30% to 40% of the weight loss seen at the 15 mg maintenance dose in clinical trials. Most patients benefit from escalation to at least 7.5 mg to 10 mg for sustained weight loss.

What's the difference between starting Zepbound and starting compounded tirzepatide? The active ingredient and mechanism are identical. Both contain tirzepatide and follow the same titration schedule. Compounded versions may include additional ingredients like B12 or glycine, which don't typically affect the side effect profile. The timeline and adaptation pattern are the same.

When should I call my provider about Zepbound side effects? Contact your provider same day for severe upper abdominal pain, persistent vomiting beyond 24 hours, difficulty swallowing, vomiting blood, black stools, or signs of severe dehydration. Contact within 24 to 48 hours for nausea persisting beyond 3 weeks at a stable dose, unintended rapid weight loss, or new symptoms after months of stable treatment.

Does everyone get nausea on Zepbound? No. About 35% to 40% of patients experience nausea during the first month on the starting dose. The remaining 60% to 65% have minimal or no nausea. Nausea rates increase with higher doses, reaching 50% to 55% at the 15 mg maintenance dose during the first 3 weeks after escalation.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Lancet. 2021.
3. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). Lancet. 2021.
4. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
5. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
6. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
7. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (SURPASS-5). JAMA. 2022.
8. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nature Medicine. 2022.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
10. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
11. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
12. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
13. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
14. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.